"The U.S. Food and Drug Administration today approved Axumin, a radioactive diagnostic agent for injection. Axumin is indicated for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated prost"...
In clinical trials using daily subcutaneous injections of leuprolide acetate in patients with prostate cancer, doses as high as 20 mg/day for up to two years caused no adverse effects differing from those observed with the 1 mg/day dose.
ELIGARD® is contraindicated in patients with hypersensitivity to GnRH, GnRH agonist analogs or any of the components of ELIGARD® . Anaphylactic reactions to synthetic GnRH or GnRH agonist analogs have been reported in the literature.
ELIGARD® may cause fetal harm when administered to a pregnant woman. Expected hormonal changes that occur with ELIGARD® treatment increase the risk for pregnancy loss and fetal harm when administered to a pregnant woman [see Use in Specific Populations)]. ELIGARD® is contraindicated in women who are or may become pregnant. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be informed of the potential hazard to the fetus.
Last reviewed on RxList: 4/25/2016
Additional Eligard Information
Eligard - User Reviews
Eligard User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.